In advanced cancer it may be advantageous to induce Erk1/2 activation in order to promote cell cycle arrest, while in hematopoietic cancers it may be beneficial to inhibit Raf induced proliferation and drug resistance. This evidence concerns the gene MAPK3 and hematopoietic and lymphoid cell neoplasm.